Skip to main content
logo
Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London flag London · Delayed Price · Currency is GBP · Price in USD
396.66
+4.58 (1.17%)
At close: Aug 1, 2025

Heartland Financial USA Revenue

Alnylam Pharmaceuticals had revenue of $594.19M USD in the quarter ending March 31, 2025, with 20.20% growth. This brings the company's revenue in the last twelve months to $2.35B, up 17.21% year-over-year. In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B with 22.97% growth.

Revenue (ttm)
$2.35B
Revenue Growth
+17.21%
P/S Ratio
22.13
Revenue / Employee
$1.05M
Employees
2,230
Market Cap
39.76B

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 20242.25B419.95M22.97%
Dec 31, 20231.83B790.87M76.23%
Dec 31, 20221.04B193.13M22.88%
Dec 31, 2021844.29M351.43M71.31%
Dec 31, 2020492.85M273.10M124.28%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
AstraZeneca41.24B
GSK plc31.63B
Haleon11.23B
Smith & Nephew4.64B
ConvaTec Group1.72B
Hikma Pharmaceuticals2.50B
HUTCHMED (China)503.39M
Oxford Nanopore Technologies183.19M
Revenue Rankings

Alnylam Pharmaceuticals News

More News